1. Juli 2026

CeQur SA, a Swiss medical device company committed to simplifying the lives of people with diabetes by revolutionizing insulin-delivery solutions, announced the close of a USD 100 million Series E equity financing.

This financing is backed by a growing demand for CeQur Simplicity™, which is FDA cleared. CeQur will use the funds to further accelerate growth across every dimension of its commercial operations.

Walder Wyss AG advised CeQur SA in the financing. The team was led by Patrick W. Vogel (Partner, Corporate/M&A) and included André Kuhn (Partner, Corporate/M&A and Notarial services), Caroline Sauthier (Senior Associate, Corporate/M&A), Marina Srienz (Associate, Corporate/M&A and Notarial services) and Laurent Schmidt (Managing Associate, Corporate/M&A).